SCHEMBL7183680

SCHEMBL7183680

COc1cc(OC)c(C(=O)C(c2ccccc2)C(C)(C)P=O)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.41
ATM Q13315 2/20 0.41
CYP3A4 P08684 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
LPAR1 Q92633 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
HTT P42858 1/20 0.37
PTPN1 P18031 1/20 0.37
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174806 0.88 CA12 (0.46) KMT2AATMMAPTMEN1L3MBTL1
SCHEMBL7190083 0.80 FABP4 (0.43) KMT2AATMMAPTMEN1L3MBTL1
SCHEMBL7179709 0.79 TDP1 (0.37) KMT2AATMCYP3A4TP53MAPT
SCHEMBL7183576 0.79 KMT2A (0.44) KMT2AATMCYP3A4TP53MAPT
SCHEMBL29504856 0.76 LMNA (0.47) KMT2AATMCYP3A4TP53MAPT
SCHEMBL7178170 0.76 L3MBTL1 (0.37) KMT2AATMMEN1L3MBTL1SMN1; SMN2
SCHEMBL7180696 0.75 TDP1 (0.46) KMT2AATMCYP3A4TP53MAPT
SCHEMBL7182262 0.75 L3MBTL1 (0.42) ATMCYP3A4L3MBTL1TDP1HTT
SCHEMBL7183493 0.74 L3MBTL1 (0.38) KMT2AATMMEN1L3MBTL1MAPK1
SCHEMBL27519981 0.73 KMT2A (0.40) KMT2AATMCYP3A4TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885ATM 2823/4885CYP3A4 1652/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885ATM 2935/4885CYP3A4 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.